Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
176(3): 161723 Cederblad G, Harper P, Lindgren K
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
The best sources are green, leafy vegetables, so dig into those salads
In particular, effects such as increased gut microbiota richness and diversity and decreased Firmicutes/Bacteroidetes ratio have been reported, demonstrating the potential of ITCs for obesity prevention
US$ 27.68
US$ 28.64
US$ 25.32
US$ 28.55
US$ 20.19
